Literature DB >> 20815659

Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.

Pamela L Rice1, Bradley S Barrett, Jason M Fritz, Mary C Srebernak, Lori R Kisley, Alvin M Malkinson, Lori D Dwyer-Nield.   

Abstract

The inflammatory cytokines tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ) stimulate production of the inflammatory mediators prostaglandin E₂ (PGEγ), prostacyclin (PGIγ), and nitric oxide (NO) in cultured lung epithelial cells. Pretreatment of these cells with the selective MEK1/2 (mitogen-activated protein kinase/extracellular signal-regulated kinase [ERK] kinase 1/2) inhibitor U0126 blocked ERK1/2 activation and inhibited cytokine-induced production of these inflammatory mediators. Primary bronchiolar epithelial Clara cells treated with TNFα and IFNγ also produced increased PGE₂, PGI₂, and NO, and PG and NO production was decreased by MEK inhibition. U0126 differentially affected cyclooxygenase (COX)-1, COX-2, and inducible NO synthase (iNOS) expression in cell lines, however, suggesting that MEK1/2 regulates prostanoid and NO production by means other than inducing their biosynthetic enzymes. Functionally, inhibition of MEK1/2 caused G1 cell cycle arrest and decreased cyclin D1 expression, but these effects were not related to decreased prostanoid production. These results indicate separate proinflammatory and proliferative roles for ERK1/2 in lung epithelial cells. During lung tumor formation in vivo, ERK1/2 phosphorylation increased as lung tumors progressed. Since tumor-derived cells were more sensitive than nontumorigenic cells to the antiproliferative effects of U0126, MEK1/2 inhibition may serve as an attractive chemotherapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20815659      PMCID: PMC3084151          DOI: 10.3109/01902148.2010.491891

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  61 in total

1.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

Review 2.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

3.  Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism.

Authors:  M Hesse; M Modolell; A C La Flamme; M Schito; J M Fuentes; A W Cheever; E J Pearce; T A Wynn
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

4.  Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.

Authors:  P L Rice; R J Goldberg; E C Ray; L J Driggers; D J Ahnen
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

5.  Cyclin D1 as a proliferative marker regulating retinoblastoma phosphorylation in mouse lung epithelial cells.

Authors:  C L Mamay; I E Schauer; P L Rice; A McDoniels-Silvers; L D Dwyer-Nield; M You; R A Sclafani; A M Malkinson
Journal:  Cancer Lett       Date:  2001-07-26       Impact factor: 8.679

6.  Indomethacin reduces lung adenoma number in A/J mice.

Authors:  T W Moody; J Leyton; H Zakowicz; T Hida; Y Kang; S Jakowlew; L You; L Ozbun; H Zia; J Youngberg; A Malkinson
Journal:  Anticancer Res       Date:  2001 May-Jun       Impact factor: 2.480

7.  Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation.

Authors:  A S Kristof; J Marks-Konczalik; J Moss
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

8.  High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors.

Authors:  A K Bauer; L D Dwyer-Nield; A M Malkinson
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

9.  Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer.

Authors:  Robert L Keith; York E Miller; Yasushi Hoshikawa; Mark D Moore; Tracy L Gesell; Bifeng Gao; Alvin M Malkinson; Heiko A Golpon; Raphael A Nemenoff; Mark W Geraci
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

10.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

View more
  4 in total

1.  Secondhand Smoke-Prevalent Polycyclic Aromatic Hydrocarbon Binary Mixture-Induced Specific Mitogenic and Pro-inflammatory Cell Signaling Events in Lung Epithelial Cells.

Authors:  Ross S Osgood; Brad L Upham; Pierre R Bushel; Kalpana Velmurugan; Ka-Na Xiong; Alison K Bauer
Journal:  Toxicol Sci       Date:  2017-05-01       Impact factor: 4.849

2.  Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation.

Authors:  Jason M Fritz; Lori D Dwyer-Nield; Alvin M Malkinson
Journal:  Mol Cancer       Date:  2011-06-24       Impact factor: 27.401

3.  Polycyclic aromatic hydrocarbon-induced signaling events relevant to inflammation and tumorigenesis in lung cells are dependent on molecular structure.

Authors:  Ross S Osgood; Brad L Upham; Thomas Hill; Katherine L Helms; Kalpana Velmurugan; Pavel Babica; Alison K Bauer
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

4.  Bronchoalveolar Lavage Fluid Utilized Ex Vivo to Validate In Vivo Findings: Inhibition of Gap Junction Activity in Lung Tumor Promotion is Toll-Like Receptor 4-Dependent.

Authors:  Thomas Hill; Ross S Osgood; Kalpana Velmurugan; Carla-Maria Alexander; Brad L Upham; Alison K Bauer
Journal:  J Mol Biomark Diagn       Date:  2013-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.